OB
HIV in Pregnancy
search
HIV in Pregnancy
, Perinatal HIV Transmission, Pregnancy Related HIV Concerns, Maternal HIV
See Also
HIV Complications
Pediatric HIV
Epidemiology
Women with
AIDS
are young: >80% are between ages 18-44 years
HIV
Prevalence
in U.S. obstetrics patients: 1-5%
Risks of vertical transmission
HIV Viral Load
<1000 copies per ml: 2% transmission
HIV Viral Load
>1000 copies/ml
Untreated woman with HIV: 25% transmission
AZT used intrapartum: 5-8% transmission
AZT and Ceserean delivery: 2% transmission
Perinatal
HIV Infection
Neonatal HIV has been reduced 95% since the 1990s in the U.S.
Of the 5000 infants born to HIV mothers in U.S. per year, 73 infants acquired
HIV Infection
(2017)
Taylor (2017) JAMA Pediatr 171(5): 435-42 [PubMed]
Racial discrepancy in Perinatally acquired HIV in United States (2009, CDC)
Black patients: 9.9 in 100,000 live births
Hispanic patients: 1.7 in 100,000 live births
White patients: 0.1 in 100,000 live births
http://www.cdc.gov/hiv/risk/gender/pregnantwomen/index.html
Risk Factors
Perinatal HIV Transmission Factors
Risks of transmissions (13-39% with
Zidovudine
)
Higher levels of maternal viremia (>1000 copies/ml)
HIV core
Antigen
emia
Lower maternal
CD4 Count
Advanced clinical HIV disease
Maternal immune factors and Viral factors
Primary HIV Infection
during pregnancy
Chorioamnionitis
Other
Sexually Transmitted Disease
Unprotected intercourse during pregnancy
"Hard drug" use during pregnancy
Invasive monitoring (e.g. fetal scalp electrodes)
Premature birth or low birthweight infant
Rupture of Membranes
Artificial Rupture of Membranes
Delivery more than 4 hours after ruptured membranes
Instrumental deliveries (i.e. forceps or vacuum)
DeLee Suction
Vaginal Delivery
Advanced maternal age
First born of twins born to an HIV infected mother
Factors that decrease risk of transmission
Higher levels of neutralizing
HIV Antibody
titers
Antibodies to certain
Epitope
s of GP 120
Elective
Cesarean Section
Zidovudine
(AZT)
Less invasive monitoring and intrapartum procedures
Mechanisms
Vertical Transmission (Maternal to Child)
Responsible for 90% of
Pediatric HIV
cases
In Utero transmission (30%)
Detected by PCR or
Blood Culture
Cord blood can not be used
Results obtained in <48 hours
Intrauterine
HIV Transmission
occurs early pregnancy
Study of 124 HIV+ obstetric patients over 4 years
Spontaneous Abortion
s 14 (11%) between 8-32 weeks
HIV Positive on autopsy: 7 of 14 fetuses (50%)
Reference
Langston (1995) J Infect Dis 172:1451-60 [PubMed]
Worse outcome then intrapartum transmission
Associated with rapid HIV progression
Newborn predictors of rapid course
Hepatosplenomegaly
Lymphadenopathy
CD4+
Lymphocyte
s <30%
HIV PCR
positive within first week of life
Mayaux (1996) JAMA 275:606-10 [PubMed]
Intrapartum Transmission (70%)
Mechanism
Direct contact with maternal genital secretions
Maternal-fetal micro transfusions
Occur during labor as in
Hepatitis B
Possible ascending infections
Similar mechanism as
Group B Streptococcus
Increased transmission if Membranes Ruptured > 4h
Infants subsequent Cultures
Negative Culture or PCR within first 48 hours
Positive Culture within 7-90 days after birth
Increased intrapartum transmission risk factors
Women not on HIV
Antiretroviral
therapy (or <4 weeks of treatment before delivery)
Advanced Maternal HIV disease
HIV RNA
load >50 copies/ml (insufficient HIV suppression, indicating
Cesarean Section
)
HIV Viral Load
>1000 copies/ml is associated with highest risk of vertical transmission
First twin delivered
Postpartum transmission
Breast Feeding
is contraindicated in Maternal HIV
Labs
Prenatal
HIV Test
ing should be encouraged for all women
Universal
HIV Screening
for all women as part of
Prenatal Lab
s
If HIV positive, start
Antiretroviral
therapy at time of diagnosis
Re-test HIV Negative women in third trimester if high risk (e.g.
IVDA
, STD risk, sex work)
Expedited
HIV Test
for HIV status unknown in active labor presentation
If HIV positive, start intrapartum
Zidovudine
for mother and
Antiretroviral
s for infant on delivery
See
Pediatric HIV
(for testing in the infant)
Viral load and
CD4 Count
baseline and in each trimester
PPD in second trimester
Management
Gene
ral Measures
Treat all
Sexually Transmitted Disease
s
Prevent opportunistic infections
Diagnose Maternal HIV early
Delivery within 4 hours of
Rupture of Membranes
Delivery by elective, scheduled
Cesarean Section
at 38 weeks
NSVD
may be considered if viral load <1000 copies/ml
Cesarean Section
does not reduce transmission if
Labor starts prior to ceserean
Spontaneous
Rupture of Membranes
Use best clinical evidence to estimate gestation
Avoid
Amniocentesis
Use prophylactic
Antibiotic
s during Ceserean Section
Most indicated in lower
CD4 Count
s
Lactation
is contraindicated (risk of
HIV Transmission
)
Update
Vaccination
s as needed
Influenza Vaccine
Pneumococcal Vaccine
Management
Anti-Retroviral Therapy
Treat HIV-infected pregnant women and infants!
Mother on
Antiretroviral
drugs after 14 weeks
NIH recommends same treatment as non-pregnant
Consider multiple
Retrovir
al drugs
Includes the use of
Protease Inhibitor
s
(1999) MMWR Morb Mortal Wkly Rep 47(RR-5):1-41 [PubMed]
Intravenous
Zidovudine
(ZDV) during labor
Infants treated in first 6 weeks of life
Decreases likelihood of maternal-infant transmission
Zidovudine
(ZDV) reduces overall transmission 25% to 8%
Peripartum ZDV reduces transmission by 30%
Zidovudine
(ZDV) Protocol for HIV positive Mothers
Antepartum (start at 14 weeks gestation)
Consider multi-
Antiretroviral
drug therapy
Zidovudine
(AZT) 100 mg PO 5 times per day
Intrapartum
Indicated for
HIV RNA
Load >1000 copies/ml at delivery (or unknown viral load)
Load: AZT 2 mg/kg over 1 hour
Maintenance: AZT 1 mg/kg/hour until delivery
Newborn
See
Pediatric HIV
for
Newborn HIV Prophylaxis
protocol
HIV Prophylaxis
started within 6 hours of delivery
Other protocols
Nevirapine
appears more effective than AZT
Nevirapine
protocols were being developed as of 20 years ago, but ZDV continues to be mainstay
Guay (1999) Lancet 354:795-802 [PubMed]
Resources
See HIV Resources
Antiretroviral
Pregnancy Registry
Phone: 800-258-4263
References
(1997) Int J Gynaecol Obstet 57:73-80 [PubMed]
Krist (2001) Am Fam Physician 63(1):107-122 [PubMed]
Krist (2002) Am Fam Physician 65(10):2049-56 [PubMed]
Lindegren (1999) JAMA 282:531-8 [PubMed]
Landesman (1996) N Engl J Med 334:1617-23 [PubMed]
Vijayan (2021) Am Fam Physician 104(1): 58-62 [PubMed]
Type your search phrase here